canertinib has been researched along with crizotinib in 6 studies
Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (crizotinib) | Trials (crizotinib) | Recent Studies (post-2010) (crizotinib) |
---|---|---|---|---|---|
124 | 9 | 65 | 1,780 | 112 | 1,718 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
Bharate, SB; Raghuvanshi, R | 1 |
de Bont, ES; den Dunnen, WF; Diks, SH; Hoving, EW; Lourens, HJ; Meeuwsen-de Boer, T; Plasschaert, SL; Zomerman, WW | 1 |
Bhargava, R; Chen, ZH; Hamilton, R; Liu, S; Luketich, JD; Luo, JH; Michalopoulos, GK; Monga, SP; Nalesnik, M; Nelson, JB; Pennathur, A; Tao, J; Tseng, G; Yu, YP | 1 |
6 other study(ies) available for canertinib and crizotinib
Article | Year |
---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Exogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell Lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Hepatocyte Growth Factor; Humans; Medulloblastoma; Morpholines; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Signal Transduction | 2015 |
MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
Topics: alpha-Mannosidase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Crizotinib; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Fusion; Golgi Apparatus; Humans; Liver Neoplasms; Mice; Mice, Knockout; Mice, SCID; Morpholines; Neoplasm Invasiveness; Neoplasm Transplantation; NIH 3T3 Cells; Oncogene Proteins, Fusion; Oncogenes; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyrazoles; Pyridines; RNA Interference; Time Factors; Transfection; Tumor Burden | 2017 |